A study of intranasally administered interferon A (rIFN-α2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers
The efficacy of interferon A (rIFN-α2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (1...
Saved in:
| Published in | Epidemiology and infection Vol. 101; no. 3; pp. 611 - 621 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cambridge, UK
Cambridge University Press
01.12.1988
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0950-2688 1469-4409 |
| DOI | 10.1017/S0950268800029484 |
Cover
| Abstract | The efficacy of interferon A (rIFN-α2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18–65 years) self-administered 1·5, 3·0 and 6·0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms. |
|---|---|
| AbstractList | The efficacy of interferon A (rIFN-α2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18–65 years) self-administered 1·5, 3·0 and 6·0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms. The efficacy of interferon A (rIFN- alpha 2A), an Escherichia coli -derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18-65 years) self-administered 1 multiplied by 5, 3 multiplied by 0 and 6 multiplied by 0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. The efficacy of interferon A (rIFN-alpha 2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18-65 years) self-administered 1.5, 3.0 and 6.0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms.The efficacy of interferon A (rIFN-alpha 2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18-65 years) self-administered 1.5, 3.0 and 6.0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms. The efficacy of interferon A (rIFN-α2A), an Escherichia coli -derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18–65 years) self-administered 1·5, 3·0 and 6·0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms. The efficacy of interferon A (rIFN-alpha 2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18-65 years) self-administered 1.5, 3.0 and 6.0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days. The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%). No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms. |
| Author | Saunders, N. A. Tannock, G. A Gillett, R. S Barry, R. D Herd, R. Reid, A. L. A Gillett, S. M Hensley, M. J |
| AuthorAffiliation | Faculty of Medicine, University of Newcastle, Royal Newcastle Hospital, New South Wales, Australia |
| AuthorAffiliation_xml | – name: Faculty of Medicine, University of Newcastle, Royal Newcastle Hospital, New South Wales, Australia |
| Author_xml | – sequence: 1 givenname: G. A surname: Tannock fullname: Tannock, G. A organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 2 givenname: S. M surname: Gillett fullname: Gillett, S. M organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 3 givenname: R. S surname: Gillett fullname: Gillett, R. S organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 4 givenname: R. D surname: Barry fullname: Barry, R. D organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 5 givenname: M. J surname: Hensley fullname: Hensley, M. J organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 6 givenname: R. surname: Herd fullname: Herd, R. organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 7 givenname: A. L. A surname: Reid fullname: Reid, A. L. A organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia – sequence: 8 givenname: N. A. surname: Saunders fullname: Saunders, N. A. organization: Faculty of Medicine, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales, 2300, Australia |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7146956$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/3215290$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkt9u0zAYxSM0NLrBAyCB5AuE4CJgO3Gc3CBVg42haggVri3HcVYX1w62Uy3PxBUvwjNh06r8k8ZNIuV3zufjfOckOzLWyCx7iOALBBF9uYQNgbiqawghbsq6vJPNUFk1eVnC5iibJZwnfi878X4dVQ2u6XF2XGBEcANn2dc58GHsJmB7oExw3HDPtZ4A7zbKKB-kk10i0vXSWQPm4Jm7PL_Kv3_D8-egtw6ElQRecm8N12BwdlhNmt8on0YaHkYXP29VeirTSxGUNT9Z8o3DIB1w0g9REKybQIwgQlSCleQ6rCawtXqMx0vn72d3e669fLB_n2afzt98PHubL95fXJ7NF7kghIYcFZD3tJKQdrBqa9qKFtYNoqSCsi46SXuCOki6ohaCdC0lGFc46kTV9RKXZXGavdrNHcZ2Izsh03_RbHBqw93ELFfsT2LUil3bLcO4bEpcxAFP9wOc_TJKH9hGeSG15kba0TNaVxjTpvqvEBFEICppFD7-PdIhy36PkT_Zc-4F133co1D-IKOpFCSdh3Yy4az3TvYHBYIsNYr906jooX95hAo8bTHeXelbnY92zrWPq_2Vua4K3JCI8x1OLbs5YO4-s4oWlLDq4gNbwGVx9XrZsHdRX-yD8E3rVHct2dqOLrbO3xLiB8Fu-xs |
| CODEN | EPINEU |
| CitedBy_id | crossref_primary_10_1016_S1473_3099_02_00221_9 crossref_primary_10_1371_journal_pgph_0000231 crossref_primary_10_1007_s11538_007_9281_2 crossref_primary_10_1371_journal_pone_0026239 crossref_primary_10_1002_jmv_22234 crossref_primary_10_1002_14651858_CD002743_pub2 crossref_primary_10_1016_j_ijid_2016_05_013 crossref_primary_10_1016_S1473_3099_11_70142_6 crossref_primary_10_1086_313696 |
| Cites_doi | 10.1056/NEJM198601093140201 10.1016/0166-3542(86)90011-2 10.1128/AAC.26.1.31 10.1016/S0140-6736(82)91031-5 10.1016/S0140-6736(73)90714-9 10.2307/2344614 10.1093/infdis/150.2.181 10.1093/oxfordjournals.bmb.a072072 10.1093/infdis/151.4.731 10.1093/oxfordjournals.bmb.a072081 10.1128/AAC.14.4.596 10.1056/NEJM198601093140202 10.1016/0166-3542(85)90037-3 10.1093/infdis/154.1.128 10.1093/infdis/148.3.543 |
| ContentType | Journal Article |
| Copyright | Copyright © Cambridge University Press 1988 Copyright 1988 Cambridge University Press 1989 INIST-CNRS |
| Copyright_xml | – notice: Copyright © Cambridge University Press 1988 – notice: Copyright 1988 Cambridge University Press – notice: 1989 INIST-CNRS |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 5PM |
| DOI | 10.1017/S0950268800029484 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Biology |
| EISSN | 1469-4409 |
| EndPage | 621 |
| ExternalDocumentID | PMC2249423 3215290 7146956 10_1017_S0950268800029484 3863295 ark_67375_6GQ_L0S3NDS9_J |
| Genre | Controlled Clinical Trial Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Australia |
| GeographicLocations_xml | – name: Australia |
| GroupedDBID | --- -1D -1F -2P -2V -E. -~6 -~N -~X ..I .FH .GJ 09C 09E 0E1 0R~ 29G 3O- 3V. 4.4 53G 5GY 5VS 6PF 6~7 74X 74Y 7RV 7X7 7~V 88A 88E 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 9M5 AAAZR AABES AABWE AACGO AACJH AAGFV AAGKA AAKDD AAKTX AAMNQ AANCE AANRG AARAB AASVR AATID AAUIS AAUKB AAWTL ABBHK ABBXD ABFBI ABITZ ABKKG ABKMT ABLJU ABMWE ABOCM ABPLY ABQTM ABQWD ABROB ABTCQ ABTLG ABUWG ABVFV ABVZP ABWCF ABXAU ABXSQ ABZCX ABZUI ACBEK ACBMC ACETC ACGFS ACIMK ACMRT ACPRK ACUIJ ACZBM ACZUX ACZWT ADACV ADAZD ADBBV ADDNB ADFEC ADKIL ADOVH ADOVT ADQXQ ADULT ADVJH AEBAK AEBPU AEHGV AEMTW AENCP AENEX AEUPB AEXZC AEYHU AEYYC AFFNX AFFUJ AFKQG AFKRA AFKSM AFLOS AFLVW AFRAH AFRIC AFUTZ AGABE AGJUD AGLWM AHIPN AHLTW AHMBA AHQXX AHRGI AIGNW AIHIV AIOIP AISIE AJ7 AJCYY AJPFC AJQAS AKZCZ ALMA_UNASSIGNED_HOLDINGS ALVPG ALWZO AN0 ANPSP AOIJS AQJOH AQVQM ARABE ARZZG ATUCA AUXHV AYIQA AZGZS BBLKV BBNVY BCGOX BENPR BESQT BGHMG BHPHI BJBOZ BKEYQ BLZWO BMAJL BNQBC BPHCQ BQFHP BRIRG BVXVI C0O CAG CBIIA CCPQU CCQAD CCUQV CDIZJ CFAFE CFBFF CGQII CHEAL CJCSC COF CS3 CTKSN DCCCD DOHLZ DOOOF DU5 EBS EGQIC EJD EMOBN EX3 F5P FYUFA GROUPED_DOAJ HCIFZ HG- HGD HMCUK HQ3 HST HTVGU HYE HZ~ I.6 I.7 I.9 IKXGN IOEEP IOO IPSME IPYYG IS6 I~P J36 J38 J3A JAAYA JBMMH JENOY JHFFW JHPGK JKPOH JKQEH JLS JLXEF JPM JQKCU JSG JSODD JST JVRFK KAFGG KC5 KCGVB KFECR L7B L98 LHUNA LK8 LW7 M-V M0L M1P M7P M7~ M8. NAPCQ NIKVX NMFBF NZEOI O9- OK1 OVD OYBOY P2P PQQKQ PROAC PSQYO Q2X RAMDC RCA RIG ROL RPM RR0 S6- S6U SA0 SAAAG SY4 T9M TEORI UCJ UKHRP UT1 UU6 WFFJZ WH7 WOW WQ3 WXU WXY WYP ZDLDU ZGI ZJOSE ZMEZD ZXP ZYDXJ ~02 ~V1 AAFWJ AAKNA AATMM ABGDZ ABVKB ABXHF ACAJB ACDLN ACEJA ACHIC ACRPL ADNMO AEMFK AENGE AEUYN AFPKN AFZFC AGQPQ AKMAY ANOYL BSCLL M48 PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO ABHFL ACOZI ALIPV AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c557t-130af76e07d06b87bcb08917560e83de7f51d05d38cc5db752262b87c6dfe2443 |
| IEDL.DBID | IKXGN |
| ISSN | 0950-2688 |
| IngestDate | Thu Aug 21 18:34:49 EDT 2025 Thu Sep 04 19:41:08 EDT 2025 Thu Sep 04 22:23:26 EDT 2025 Wed Feb 19 02:36:31 EST 2025 Mon Jul 21 09:17:12 EDT 2025 Thu Apr 24 23:04:13 EDT 2025 Tue Jul 01 02:33:54 EDT 2025 Thu Jul 03 21:28:56 EDT 2025 Sun Aug 31 06:49:37 EDT 2025 Thu May 09 22:59:37 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Infection Human Prevention Upper respiratory tract Viral disease ENT disease Interferon Intranasally administration |
| Language | English |
| License | https://www.cambridge.org/core/terms CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c557t-130af76e07d06b87bcb08917560e83de7f51d05d38cc5db752262b87c6dfe2443 |
| Notes | istex:D5C31125AB246394089060B2CC31E386594044A0 PII:S0950268800029484 ark:/67375/6GQ-L0S3NDS9-J ArticleID:02948 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/5FE4D37725674BF68CCC4AA1DCC8615A/S0950268800029484a.pdf/div-class-title-a-study-of-intranasally-administered-interferon-a-a-href-fn01-ref-type-fn-a-rifn-2a-for-the-seasonal-prophylaxis-of-natural-viral-infections-of-the-upper-respiratory-tract-in-healthy-volunteers-div.pdf |
| PMID | 3215290 |
| PQID | 15150147 |
| PQPubID | 23462 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2249423 proquest_miscellaneous_78622796 proquest_miscellaneous_15150147 pubmed_primary_3215290 pascalfrancis_primary_7146956 crossref_primary_10_1017_S0950268800029484 crossref_citationtrail_10_1017_S0950268800029484 jstor_primary_3863295 istex_primary_ark_67375_6GQ_L0S3NDS9_J cambridge_journals_10_1017_S0950268800029484 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1988-12-01 |
| PublicationDateYYYYMMDD | 1988-12-01 |
| PublicationDate_xml | – month: 12 year: 1988 text: 1988-12-01 day: 01 |
| PublicationDecade | 1980 |
| PublicationPlace | Cambridge, UK |
| PublicationPlace_xml | – name: Cambridge, UK – name: Cambridge – name: England |
| PublicationTitle | Epidemiology and infection |
| PublicationTitleAlternate | Epidemiol. Infect |
| PublicationYear | 1988 |
| Publisher | Cambridge University Press |
| Publisher_xml | – name: Cambridge University Press |
| References | S0950268800029484_ref009 Coulton (S0950268800029484_ref003) 1974 S0950268800029484_ref008 Armitage (S0950268800029484_ref001) 1977 Zarr (S0950268800029484_ref019) 1974 S0950268800029484_ref010 Dixon (S0950268800029484_ref004) 1985 S0950268800029484_ref005 S0950268800029484_ref016 S0950268800029484_ref015 S0950268800029484_ref007 S0950268800029484_ref018 S0950268800029484_ref006 S0950268800029484_ref017 S0950268800029484_ref012 S0950268800029484_ref011 S0950268800029484_ref014 S0950268800029484_ref002 S0950268800029484_ref013 |
| References_xml | – ident: S0950268800029484_ref006 doi: 10.1056/NEJM198601093140201 – start-page: 221 volume-title: Biostatistical Analysis year: 1974 ident: S0950268800029484_ref019 – ident: S0950268800029484_ref012 doi: 10.1016/0166-3542(86)90011-2 – ident: S0950268800029484_ref007 doi: 10.1128/AAC.26.1.31 – ident: S0950268800029484_ref018 doi: 10.1016/S0140-6736(82)91031-5 – ident: S0950268800029484_ref013 doi: 10.1016/S0140-6736(73)90714-9 – start-page: 437 volume-title: BMDP statistical software year: 1985 ident: S0950268800029484_ref004 – ident: S0950268800029484_ref015 doi: 10.2307/2344614 – ident: S0950268800029484_ref017 doi: 10.1093/infdis/150.2.181 – ident: S0950268800029484_ref002 doi: 10.1093/oxfordjournals.bmb.a072072 – ident: S0950268800029484_ref005 doi: 10.1093/infdis/151.4.731 – ident: S0950268800029484_ref016 doi: 10.1093/oxfordjournals.bmb.a072081 – ident: S0950268800029484_ref008 doi: 10.1128/AAC.14.4.596 – start-page: 204 volume-title: Statistics in Medicine year: 1974 ident: S0950268800029484_ref003 – ident: S0950268800029484_ref010 doi: 10.1056/NEJM198601093140202 – ident: S0950268800029484_ref009 doi: 10.1016/0166-3542(85)90037-3 – start-page: 456 volume-title: Statical Methods in Medical Research year: 1977 ident: S0950268800029484_ref001 – ident: S0950268800029484_ref014 doi: 10.1093/infdis/154.1.128 – ident: S0950268800029484_ref011 doi: 10.1093/infdis/148.3.543 |
| SSID | ssj0009287 |
| Score | 1.3740755 |
| Snippet | The efficacy of interferon A (rIFN-α2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated... The efficacy of interferon A (rIFN-α2A), an Escherichia coli -derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated... The efficacy of interferon A (rIFN-alpha 2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was... The efficacy of interferon A (rIFN- alpha 2A), an Escherichia coli -derived interferon, in the prophylaxis of acute upper respiratory tract infection, was... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref jstor istex cambridge |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 611 |
| SubjectTerms | Administration, Intranasal Adult Aged Antibodies Antibodies - analysis Biological and medical sciences Diseases Dosage Female Human viral diseases Humans Infections Infectious diseases Interferon alpha-2 Interferon Type I - administration & dosage Interferon-alpha - administration & dosage Interferons Male Medical sciences Medications Middle Aged Mucus - analysis Placebos Prospective Studies Recombinant Proteins Respiratory tract infections Respiratory Tract Infections - prevention & control Seasons Symptoms Viral diseases Viral diseases of the respiratory system and ent viral diseases Virus Diseases - prevention & control Viruses |
| Title | A study of intranasally administered interferon A (rIFN-α2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers |
| URI | https://www.cambridge.org/core/product/identifier/S0950268800029484/type/journal_article https://api.istex.fr/ark:/67375/6GQ-L0S3NDS9-J/fulltext.pdf https://www.jstor.org/stable/3863295 https://www.ncbi.nlm.nih.gov/pubmed/3215290 https://www.proquest.com/docview/15150147 https://www.proquest.com/docview/78622796 https://pubmed.ncbi.nlm.nih.gov/PMC2249423 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1db9MwFLXGKiQkNMHYtDA2_IAQIKLm2_ZjBXQfQCVUJvUtcmJHVERplbbS-pt44o_wm7jXTtJ1wCRe6-ubNPcmPraPzyXkhQxkVsTac33FpRsVQroyyqXLtfKVYlEecjyN_HmUnF9Fl5N4skMm7VkYpFV2GgdmJ9_UR5tb-dP-VFkOja77YwAHMIGA_MOdpYhHfVy07DchSJsHf4_0ADP48Ab0Lj5OzkYbQd7AFM9DJy56aXc8jZz0Lc83dRe2xq8ehuK6pTIir1Iu4NEWtibG30Drbe7ljcFs-IjsNSiUDuzdPyY7uton921dyvU-eWgX86g9o_SE_BhQI0NLZwWdosNKLmRZrqlspHex4Ce26LrQ9ayiA_qqvhiO3F8_g8FrCriYAs6kuB6JwJ_C_UJ0S3k9XaBLIy4KPyPfuKQtPawybdhvNZ_rmtYbUgBd4tkusKT2GOea4kcWLg9Y9oBcDT98fXfuNlUe3DyO2dKFQVQWLNEeU16ScZblmcdhEglQTPNQaVbEvvJiFfI8j1XGEDAGYJcnqtAATsJDslvNKn1EaCZj5mUyEwWK-gdK8FzzyNdelHCRicghb7s4pk2iLFLLc2PpH2F3iNeGOs0bxXQs3FHe1eVN12Vu5ULuMn5p8qezlPV35NmxOE3OvqSfvHE4ej8W6aVDDkyCdYYhT8JAxA452Uq4rp3B-AcTX4c8bxMwha8GbgXJSs9W8J8BxsLkmP3bgsFUN2ACfBzahN1cHEshC88hbCuTu3YULN9uqabfjHA5wEUB8P3p_4XhmDzwBXzPDYfoGdld1it9AkhwmZ02L_WpWaT7DZxRXEk |
| linkProvider | Cambridge University Press |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1db9MwFLXGKgQSQjA2EWDMDwgBImqaL9uPFdC1W1cJdZP6FjmxIyqqtEpbaf1NPPFH-E3cayfpOmASr_X1zce9jY_t43MJeSN9meaR9tyO4tINcyFdGWbS5Vp1lGJhFnA8jXwxivtX4dkkmuyRSX0WBmmVjcaB2ck39dEWVv60PVWWQ6PL9hjAAUwgIP9wZynkYRsXLdtVCJLqxd8jLVS0gtxvDc4np6OtIK9viuehExe91DueRk76luebugs741cLQ3FdUxmRVymX8GpzWxPjb6D1NvfyxmDWe0IeVyiUdu3dPyV7ujgg921dys0BeWQX86g9o_SM_OhSI0NL5zmdosNCLuVstqGykt7Fgp_Yostcl_OCdum7ctAbub9--t33FHAxBZxJcT0SgT-F-4XozuT1dIkujbgo_Ix84xmt6WGFacN-68VCl7TckgLoCs92gSW1xzg3FD-ycHnAsofkqvfl8lPfrao8uFkUsZULg6jMWaw9prw45SzNUo_DJBKgmOaB0iyPOsqLVMCzLFIpQ8Dog10Wq1wDOAmOyH4xL_RzQlMZMS-VqchR1N9Xgmeahx3thTEXqQgd8rGJY1IlyjKxPDeW_BF2h3h1qJOsUkzHwh2zu7p8aLosrFzIXcZvTf40lrL8jjw7FiXx6ddk6I2D0eexSM4ccmgSrDEMeBz4InLI8U7CNe0Mxj-Y-DrkpE7ABL4auBUkCz1fwzMDjIXJMfu3BYOprs8E-DiyCbu9OJZCFp5D2E4mN-0oWL7bUky_GeFygIsC4PuL_wvDCXnQv7wYJsPB6PwledgR8G03fKJXZH9VrvUxoMJV-rr6g_8GIe5eNQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+study+of+intranasally+administered+interferon+A+%28rIFN-%CE%B12A%29+for+the+seasonal+prophylaxis+of+natural+viral+infections+of+the+upper+respiratory+tract+in+healthy+volunteers&rft.jtitle=Epidemiology+and+infection&rft.au=Tannock%2C+G.+A&rft.au=Gillett%2C+S.+M&rft.au=Gillett%2C+R.+S&rft.au=Barry%2C+R.+D&rft.date=1988-12-01&rft.pub=Cambridge+University+Press&rft.issn=0950-2688&rft.eissn=1469-4409&rft.volume=101&rft.issue=3&rft.spage=611&rft.epage=621&rft_id=info:doi/10.1017%2FS0950268800029484&rft.externalDocID=10_1017_S0950268800029484 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-2688&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-2688&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-2688&client=summon |